mpmcapital.com

Tasks

Avoid using deprecated HTML tags.

SEO

URL

Domain : www.mpmcapital.com/

Character length : 19

Title

MPM Capital - Powering Breakthroughs in Life Sciences

Description

Powering Breakthroughs in Life Sciences

Keywords (meta keywords)

Good! The website does not use “meta keywords”.

Open Graph Protocol

Good! The OG (Open Graph) protocol is set on this website.

locale: en_US
type: website
title: MPM Capital - Powering Breakthroughs in Life Sciences
description: Powering Breakthroughs in Life Sciences
url: http://www.mpmcapital.com/
site_name: MPM Capital

Dublin Core

Dublin Core is not used

Underscores in the URLs

Good! No underscore (_) found in the URLs.

Search engine friendly URLs

Good! The website uses SEO friendly URLs.

Checking the robots.txt file

There is robots.txt file.
https://mpmcapital.com/robots.txt

User-agent	Disallowed for the search engines
*	/wp-admin/

Social

Social Engagement

Linkedin15

Facebook Share0

Facebook Comments0

Content

Doctype

HTML 5

Encoding

Perfect! The character encoding is set: UTF-8.

Language

We have found the language localisation: ”en”.

Title

MPM Capital - Powering Breakthroughs in Life Sciences

Character length : 53

Good! The title’s length is between 10 and 70 characters.

Text / HTML ratio

Ratio : 22%

Acceptable! The text / code ratio is between 15 and 25 percent.

Headings

H1	H2	H3	H4	H5	H6
0	130	139	126	0	0

Heading structure in the source code

<H2> MPM Focus Area
<H3> Antibody agents for thetreatment of cancerRelated Investment: COSTIMWatch Now Chris Bardon, MD Oncology Impact Fund,Discusses Advances in Cancer TherapiesBloomberg Capital Markets, June 2016
<H2> MPM Investment Strategy
<H3> Fund
<H3> Investments
<H3> Exit Type
<H3> Focus Area
<H4> 23andMe
<H4> 28-7
<H4> Affymax, Inc.
<H4> Aires
<H4> Alinea Pharmaceuticals, Inc.
<H4> Allozyne, Inc.
<H4> Alnara
<H4> Amphivena
<H4> Anthera
<H4> Aratana
<H4> Archus Orthopedics, Inc.
<H4> ARYx Therapeutics, Inc.
<H4> Astute Medical
<H4> Atopix Therapeutics, Inc.
<H4> Barrier Therapeutics, Inc.
<H4> BioMarin
<H4> Blade Therapeutics
<H4> Celladon
<H4> Cellerant Therapeutics, Inc.
<H4> Cerecor Inc.
<H4> Ceregene, Inc.
<H4> Cerimon Pharmaceuticals, Inc.
<H4> CHF Solutions, Inc.
<H4> Chiasma
<H4> Clinical ink
<H4> Conatus
<H4> CoStim
<H4> CoTherix, Inc.
<H4> DigiTx Partners
<H4> Dragonfly Sciences, Inc.
<H4> EKR Therapeutics
<H4> Elixir Pharmaceuticals, Inc.
<H4> EndoGastric Solutions, Inc.
<H4> Endologix
<H4> EnteroMedics, Inc.
<H4> Epizyme
<H4> ForteBio
<H4> Harpoon Therapeutics
<H4> Helicos Biosciences Corporation
<H4> Hypnion, Inc.
<H4> Iconic
<H4> Idenix
<H4> IDUN Pharmaceuticals, Inc.
<H4> Innovative Spinal Technologies, Inc.
<H4> Intercell AG
<H4> Intracel Holdings Corporation
<H4> IOmx Therapeutics AG
<H4> iPierian
<H4> KaloBios Pharmaceuticals, Inc.
<H4> MacroGenics, Inc.
<H4> Maverick Therapeutics, Inc.
<H4> Memory Pharmaceuticals Corp.
<H4> Meritage Pharma
<H4> Mitobridge
<H4> Motus Therapeutics, Inc.
<H4> Neosil
<H4> NeoVista, Inc.
<H4> NeuroMed Pharmaceuticals, Inc.
<H4> Nevro
<H4> Oncorus
<H4> Oxagen Limited
<H4> Pacira
<H4> Peptimmune, Inc.
<H4> Pernix Therapeutics, Inc.
<H4> Pharmasset
<H4> PharmAthene, Inc.
<H4> Poniard Pharmaceuticals, Inc.
<H4> Portola Pharmaceuticals, Inc.
<H4> Potenza Therapeutics
<H4> Proteon Therapeutics
<H4> QuatRx Pharmaceuticals Company
<H4> Radius Health
<H4> Raze Therapeutics
<H4> Rhythm
<H4> Rigel Pharmaceuticals, Inc.
<H4> Rinat Neuroscience Corp.
<H4> SAI
<H4> Selexys
<H4> Semma Therapeutics
<H4> Sideris Pharmaceuticals, Inc.
<H4> Solasia
<H4> Somaxon Pharmaceuticals, Inc.
<H4> Surface Logix, Inc.
<H4> Syndax
<H4> TCR2, Inc.
<H4> Tercica, Inc.
<H4> Tetherex Pharmaceuticals Corporation
<H4> Theraclone Sciences, Inc.
<H4> Tizona Therapeutics, Inc.
<H4> Trieza Therapeutics
<H4> TriNetX
<H4> True North Therapeutics
<H4> Vaccinogen, Inc.
<H4> Valeritas
<H4> Vascular
<H4> Verastem, Inc.
<H4> Verus Pharmaceuticals, Inc.
<H4> Xanodyne Pharmaceuticals, Inc.
<H2> MPM Team
<H3> Role
<H3> Location
<H2> Patrick Baeuerle
<H3> Patrick Baeuerle, Ph.D.
<H4> Managing Director
<H2> Chris Bardon
<H3> Christiana Bardon, M.D.
<H4> Managing Director
<H2> Vinay Bhaskar
<H3> Vinay Bhaskar, Ph.D.
<H4> Principal
<H2> Laura Brass
<H3> Laura Brass, Ph.D., M.B.A.
<H4> Managing Director
<H2> Pablo Cagnoni
<H3> Pablo J. Cagnoni, M.D.
<H4> Managing Director
<H2> Lauren Cauley
<H3> Lauren Cauley
<H4> Chief Financial Officer
<H2> Thomas Ebeling
<H3> Thomas Ebeling
<H4> Medical and Scientific Advisors (OIF)
<H2> Luke Evnin
<H3> Luke Evnin, Ph.D.
<H4> Managing Director
<H2> Mitchell Finer Ph.D.
<H3> Mitchell Finer Ph.D.
<H4> Managing Director
<H2> Todd Foley
<H3> Todd Foley, M.B.A.
<H4> Managing Director
<H2> Shinichiro Fuse
<H3> Shinichiro Fuse, Ph.D.
<H4> Principal
<H2> Ansbert Gadicke
<H3> Ansbert Gadicke, M.D.
<H4> Managing Director
<H2> Bard Geesaman
<H3> Bard Geesaman, M.D., Ph.D.
<H4> Managing Director
<H2> William Greene
<H3> William Greene, M.D.
<H4> Venture Partner
<H2> Dan Hicklin
<H3> Dan Hicklin, Ph.D.
<H4> Managing Director
<H2> Robert Horvitz
<H3> H. Robert Horvitz, Ph.D.
<H4> Medical and Scientific Advisory Board (MPM & OIF)
<H2> Ed Hurwitz
<H3> Ed Hurwitz, J.D., M.B.A.
<H4> Managing Director
<H2> Briggs Morrison
<H3> Briggs Morrison, M.D.
<H4> Managing Director
<H2> Vas Narasimhan
<H3> Vas Narasimhan, M.D.
<H4> Medical and Scientific Advisory Board (MPM)
<H2> Gary Patou
<H3> Gary Patou, M.D.
<H4> Managing Director
<H2> Sarah Reed
<H3> Sarah Reed
<H4> Chief Operating Officer and General Counsel
<H2> Tony Rosenberg
<H3> Tony Rosenberg
<H4> Managing Director
<H2> David Ryan
<H3> David P. Ryan M.D.
<H4> Medical & Scientific Advisor (OIF)
<H2> Jim Scopa
<H3> Jim Scopa , J.D., M.B.A.
<H4> Managing Director
<H2> Kazumi Shiosaki
<H3> Kazumi Shiosaki, Ph.D.
<H4> Managing Director
<H2> Greg Sieczkiewicz
<H3> Greg Sieczkiewicz, J.D., Ph.D.
<H4> Managing Director & Chief IP Counsel
<H2> Elizabeth Stoner
<H3> Elizabeth Stoner, M.D.
<H4> Managing Director
<H2> Chris Varma
<H3> Chris Varma, Ph.D.
<H4> Entrepreneur-in-Residence
<H2> Contact Us
<H3> Cambridge, MA
<H3> San Francisco, CA
<H3> 2017
<H2> Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform
<H3>
<H2> Harpoon Therapeutics Announces Completion of $45M Series B Financing
<H3>
<H2> MPM Portfolio Company True North Therapeutics Acquired by Bioverativ, Inc
<H3> Upfront payment of $400M plus assumed cash, with additional payments of up to $425M contingent on the achievement of future milestones
<H2> Syndax Shares Soar as Lead Drug Clears a Mid-Stage Cancer Drug Study Hurdle
<H3>
<H2> Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis
<H3>
<H2> Inside Perspectives on Cancer Immunotherapy: An Interview with MPM’s Christiana Bardon
<H3>
<H2> FDA Approves MPM Portfolio Company Radius Health’s TYMLOS™ (abaloparatide)
<H3> Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
<H2> Meet One the Most Successful German Biotech Leaders Ever Read more about MPM’s Patrick Baeuerle
<H3>
<H2> MPM Managing Director Chris Bardon Named a Top-40 Transformer
<H3> Top innovation gurus leading the biopharma industry's transformation are recognized by MM&M
<H2> MPM Portfolio Company Oncorus Nominated for 2017 NEVY Award as Hottest Early-Stage Startup Therapeutics
<H3>
<H2> Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors
<H3>
<H2> Rhythm Announces Completion of $41 Million Mezzanine Financing
<H3> — Proceeds to finance significant expansion of genetic obesity clinical trials —
<H2> Chris Varma, Co-founder and Former President and CEO of Blueprint Medicines, Joins MPM as Entrepreneur-in-Residence
<H3>
<H2> MPM Portfolio Company Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies
<H3>
<H2> Accomplished Biotech Investor Ed Hurwitz Joins MPM as Managing Director
<H3>
<H3> 2016
<H2> MPM Portfolio Company, Astute Medical, Forms Strategic Partnership with Bio-Techne
<H3>
<H2> Novartis Signs Exclusive Option, Collaboration and License Agreement with MPM Portfolio Company Conatus Pharmaceuticals Inc.
<H3>
<H2> Oncorus®, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLC
<H3>
<H2> Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO
<H3>
<H2> TCR2 Therapeutics Launches from Stealth Mode to Accelerate Development of Novel Cancer Immunotherapies
<H3> - $44.5M Series A Financing Led by MPM Capital and F2 Ventures -
<H2> Chris Bardon, MPM Managing Director, Comments to Bloomberg on New Approaches to Medical Philanthropy
<H3> Read full article – “A Few Billionaires Are Turning Medical Philanthropy on Its Head”
<H2> Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Tumor Program Update
<H3>
<H2> Novartis Acquires MPM Portfolio Company Selexys Pharmaceuticals Corporation and SelG1 Antibody for Reduction of Pain Crises in Sickle Cell Disease
<H3>
<H2> Harpoon Therapeutics Appoints Hans-Peter Gerber, PhD, As Chief Scientific Officer
<H3>
<H2> Semma Therapeutics Announces Mark Fishman, M.D. Has Joined Its Board of Directors as Chairman
<H3>
<H2> MPM Portfolio Company Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer Institute
<H3>
<H2> Motus Therapeutics Inc., a Subsidiary of MPM Portfolio Company Rhythm Holding Co., LLC is to be Acquired by Allergan
<H3> Acquisition Announced Following Positive Results for Phase 2b Clinical Trial of Treatment for GI Disorders
<H2> True North Therapeutics Announces $45 Million Series D Financing
<H3> Financing Follows Encouraging Interim Clinical Data Announced for Lead Product Candidate, TNT009, in Cold Agglutinin Disease
<H2> True North Therapeutics Receives FDA Orphan Drug Designation for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD)
<H3>
<H2> Pacira Pharmaceuticals’ Kristen Williams is Honored as 1 of 15 “Fierce Women in Biopharma 2016”
<H3> Learn why Kristen stands out among women in the industry
<H2> iOmx Therapeutics Raises EUR 40 Million in Series A round
<H3> Company establishes top-tier investor base consisting of MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures
<H2> Three MPM Portfolio Companies (Blade, Oncorus & Rhythm) Named to FierceBiotech’s “2016 Fierce 15” List
<H3>
<H2> Radius Announces Publication of Additional Positive Results from the Phase 3 Active Trial of Osteoporosis Treatment
<H3>
<H2> Tizona Therapeutics, Inc. Appoints George Golumbeski, Ph.D., to its Board of Directors
<H3>
<H2> Osteoporosis, a Disease With Few Treatment Options, May Soon Have One More
<H3> Read coverage in NY Times and in Press Release
<H2> Aratana Secures Third FDA Approval
<H3> Animal pain drug expected to be available to veterinarians in the fall of 2016
<H2> Harvard Medical School Appoints MPM Medical and Scientific Advisory Co-Chair George Daley as New Dean
<H3> Read more in The Boston Globe
<H2> Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment
<H3>
<H2> Astellas and MPM Capital Launch DigiTx Partners
<H3>
<H2> MPM Portfolio Company Blade Therapeutics Featured in the San Francisco Business Times
<H3> The July 19 article, “Taking it personally, cutting–edge biotech snags $45 million,” discusses the latest round of funding for Blade, a company focused on finding therapies for fibrotic disease, and MPM Co-Founder Luke Evnin’s personal commitment to the cause.
<H2> Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity
<H3> Significant weight loss with targeted treatment for patients with rare genetic defect in critical weight regulation pathway
<H2> Former Bluebird Bio (BLUE) CSO Takes the Reins at Oncorus; Startup Launches with $57 Million Series A
<H3>
<H2> MPM Portfolio Company Semma Therapeutics Featured in Boston Globe
<H3> Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and Semma Therapeutics to make personalized cell-based therapies and organize clinical trials.
<H2> Chris Bardon, Managing Director for the Oncology Impact Fund, on Bloomberg Capital Markets
<H3> Discussing Advances in Cancer Therapies as the 2016 ASCO Annual Meeting Gets Underway
<H2> TriNetX Enters into Collaboration with Celgene
<H3> Advance Clinical Trial Design and Research for Next-Generation Medicines Planned
<H2> Aratana Therapeutics Granted FDA Approval of ENTYCE®
<H3> First-of-its-Kind Ghrelin Mimetic
<H2> MPM Launches $471 Million Social Impact Oncology Fund
<H3>
<H2> UBS Cancer Fund Shows Power of Impact Investing
<H3> A new oncology fund will finance academic research and access to cancer care in developing countries
<H2> UBS, MPM Seek Big ‘Impact’ in Cancer Drugs with $471M Fund
<H3> By Marie Powers, BioWorld Today, April 28, 2016
<H2> UBS Raises Record $471 Million for Oncology Impact Fund
<H3> BioSpace.com 4/27/2016
<H2> Aratana Therapeutics Granted First FDA Approval
<H3> Galliprant for the Control of Pain and Inflammation Associated with Osteoarthritis in Dogs
<H2> Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly
<H3>
<H2> Tizona Therapeutics, Inc., Completes $43 Million Series B Financing
<H3>
<H2> Radius Health Submits New Drug Application to the U.S. Food and Drug Administration for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis
<H3>
<H2> Nasdaq Welcomes Syndax Parmaceuticals, Inc. to The Nasdaq Stock Market
<H3>
<H2> Iconic Therapeutics Closes Series C Financing
<H3>
<H3> 2015
<H2> Cerecor Announces Pricing of Initial Public Offering
<H3>
<H2> Semma Therapeutics named FierceMedicalDevices’ 2015 Fierce 15
<H3>
<H2> Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab
<H3>
<H2> Syndax Raises $80 Million in Series C Financing
<H3>
<H2> Rhythm Subsidiary Raises $40 Million in Oversubscribed Financing
<H3> Financing to advance Rhythm Metabolic, Inc.'s setmelanotide program for rare genetic disorders of obesity
<H2> Epizyme Appoints Robert Bazemore President and Chief Executive Officer
<H3>
<H2> Chiasma, Inc. Prices Initial Public Offering of Common Stock
<H3>
<H2> Taking Clinical Trials Out of the Dark Ages (Clinical Ink)
<H3>
<H2> Briggs W. Morrison, M.D., CEO of Syndax, Appointed Key Strategic Advisor to MPM Capital
<H3>
<H2> Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly
<H3> Submission based on positive results from Phase 3 clinical trial
<H2> K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific Advisor
<H3>
<H2> MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company Vesuvius
<H3>
<H2> MPM closes $400 million fund
<H3>
<H2> 23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc.
<H3> With Lupus Awareness Month Underway, Study Aims to Build a 5,000-Patient Lupus Cohort to Advance Understanding of the Disease
<H2> Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics
<H3> Exclusive Collaboration Includes Option for Astellas to Acquire Potenza
<H2> Novartis International Global Head M&A and Licensing Anthony Rosenberg to join as Managing Director, effective April 1, 2015
<H3> - To serve as strategic advisor and on MPM portfolio boards to build leading companies -
<H2> Biotech Startup to Fight Diabetes on the Cellular Front
<H3> Semma Therapeutics seeks to turn success in stem research lab into a way to encourage insulin production
<H2> Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Signs Agreement with Global Pharmaceutical Company
<H3>
<H2> Ebb & Flow: Chiasma’s Private Decision
<H3>
<H2> Chiasma Announces Mark Leuchtenberger as Chief Executive Officer
<H3> Proven Business Leader to Oversee Commercialization of Octreotide Capsules
<H2> 23andMe to Create Therapeutics Group, Appoints Scientific Luminary, R&D Executive Richard Scheller, Ph.D. to Lead
<H3> Dr. Scheller Joins 23andMe’s Executive Leadership Team as Chief Science Officer and Head of Therapeutics
<H2> MPM Capital Announces Immuno-Oncology Pioneer Patrick Baeuerle to serve as Managing Director
<H3> -Top scientist and drug developer joins MPM senior team advancing breakthroughs and discoveries
<H2> Radius (RDUS) Announced Today That It Has Acquired The License To Develop And Market RAD1901 In Japan
<H3> Dinesh Purandare Hired (Former Sanofi (SAN.PA) Oncology Executive To The Position Of Senior Vice President (SVP) And Head Of Global Oncology At Radius )
<H2> Chiasma Announces Completion of $70 Million Series E Financing
<H3>
<H2> Verastem Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma
<H3>
<H2> Chiasma Appoints David Stack as Chairman of the Board; John A. Scarlett, M.D. Joins Board of Directors
<H3>
<H2> Syndax Says Immuno-oncology Discovery Happened Instead of an IPO
<H3>
<H2> Chiasma Inc. Releases Newly Published Phase 3 Study Results
<H3> Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder
<H2> Radius, Celladon and Nevro Among Top IPOs in 2014
<H3> MPM has #1, 8 and 10 out of the top 14
<H2> Radius: The Top Performing IPO of 2014
<H3> Radius, which is developing treatments for osteoporosis, is up 364% since pricing its June 6 initial public offering at 8
<H3> 2014
<H2> Radius Announces Positive Phase 3 Top-Line Results
<H3>
<H2> For Venture Capital, Biotech is Where It’s Really At
<H3>
<H2> Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin
<H3>
<H2> Aratana Featured: Start-Ups Work on Biotech Drugs for Pets
<H3>
<H2> Cerecor Inc. Closes on Initial Tranche of US$32M Series B Financing
<H3>
<H2> True North snags $22M and sets course for the clinic with a rare disease drug
<H3>
<H2> iPierian acquired by Bristol-Myers Squibb
<H3> Advances discovery strategy to pursue therapeutics for genetically defined diseases
<H2> Iconic Therapeutics Raises $20 Million to Advance Clinical Development of Wet AMD Program
<H3> William Greene, MD, Appointed Chief Executive Officer
<H2> Celladon Receives Breakthrough Therapy Designation from FDA
<H3> MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation from FDA’s Center for Biologics Evaluation and Research (CBER)
<H2> CoStim Pharmaceuticals, Inc. Acquired by Novartis
<H3>
<H2> MPM Capital and Kleiner Perkins Caufield & Byers top the list of investors with the most 2013 IPOs
<H3>
<H2> Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone
<H3>

Word cloud

exited63
therapeutics61
mpm42
oncology37
current37
read32
developing31
bio29
cancer26
managing25
director25
company23
pharmaceuticals23
cambridge20
treatment18
clinical18
novel17
announces16
portfolio15
april15
million15
financing14
medical14
drug14
capital13
diseases13
disorders13
disease12
fund12
march12
series12
development12
therapies11
san11
francisco10
august10
radius10
drugs10
fda9
research9
scientific9
new9
february9
products8
december8
phase8
chiasma8
impact8
chris8
board8
june8
syndax8
patients8
october8
appoints8
rhythm8
chief8
top7
care7
semma7

Keyword matrix

word	title	descriptions	heading
exited
therapeutics
mpm
oncology
current
read

Two Word cloud

other exited27
managing director19
director cambridge12
mpm portfolio9
read bio9
other current9

Three Word cloud

managing director cambridge10
mpm portfolio company8
managing director san4
true north therapeutics3
cambridge read bio3
for patients with2

404 Page

The website has a 404 error page.

Flash content

Good! The website does not have any flash contents.

Frame

Good! The website does not use iFrame solutions.

Images

We found 134 images on this web page.

Alternate attributes for the following 133 images are missing. Search engines use "alt" tags to understand image content efficiently. We strongly recommend fixing this issue.

Readability

Flesch–Kincaid Grade Level

9.40

Flesch Reading Ease

35.30

Coleman Liau Index

12.00

Automated Readability Index (ARI)

6.60

Dale–Chall Readability

9.50

SMOG Index

9.90

Spache Readibility

5.00

Number of letters

21185

Number of words

3839

Number of sentences

939

Average words per sentences

Number of syllables

7597

Syllables in words

7310

Average syllables in words

1.98

Number of words in first three syllables

1262

Percentage of word / syllables

32.87

Words not in Dale-Chall easy-word list

2265

Words not in Spache easy-word list

860

Technologies

Deprecated HTML elements

Good! No deprecated HTML tags are detected.

Redirection (www / not www)

Good! The web address is accessible only in one version. The version without www is redirected to the version with www.

Deprecated HTML elements

Good! No deprecated HTML tags are detected.

Printability

Suggestion! Unfortunately, no printer-friendly CSS found.

Meta Tag (viewport tag, mobile devices)

Error! The meta tag named viewport is missing.

Speed test

Server response time

The server response time is fast enough.

Table layout

Good! No nested tables found.

Render blocking resources

Good! No render blocking elements found!

Speed test – Javascript

Javascript

Error! Too many javascript files found which slows down the page load on the website.

http://www.mpmcapital.com/wp-includes/js/jquery/jquery.js?ver=1.12.4
http://www.mpmcapital.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=1.4.1
http://www.mpmcapital.com/wp-content/plugins/photo-gallery/js/bwg_frontend.js?ver=1.3.42
http://www.mpmcapital.com/wp-content/plugins/photo-gallery/js/jquery.sumoselect.min.js?ver=3.0.2
http://www.mpmcapital.com/wp-content/plugins/photo-gallery/js/jquery.mobile.js?ver=1.3.42
http://www.mpmcapital.com/wp-content/plugins/photo-gallery/js/jquery.mCustomScrollbar.concat.min.js?ver=1.3.42
http://www.mpmcapital.com/wp-content/plugins/photo-gallery/js/jquery.fullscreen-0.4.1.js?ver=0.4.1
http://www.mpmcapital.com/wp-content/plugins/photo-gallery/js/bwg_gallery_box.js?ver=1.3.42
http://www.mpmcapital.com/wp-content/plugins/contact-form-7/scripts.js
http://www.mpmcapital.com/wp-includes/js/jquery/jquery.form.js?ver=2.02
http://www.mpmcapital.com/wp-content/plugins/contact-form-7/includes/js/jquery.form.min.js?ver=3.51.0-2014.06.20
http://www.mpmcapital.com/wp-content/plugins/contact-form-7/includes/js/scripts.js?ver=4.7
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/vendor/jquery-ui-1.10.4.custom.min.js?ver=4.7.5
http://www.mpmcapital.com/wp-includes/js/imagesloaded.min.js?ver=3.2.0
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/vendor/video.js?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/vendor/bigvideo.js?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/vendor/jquery.flexslider.js?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/vendor/rotate-patch.js?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/vendor/waypoints.min.js?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/vendor/mediaBoxes.js?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/vendor/skrollr.min.js?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/built.min.js?ver=4.7.5
http://www.mpmcapital.com/wp-includes/js/wp-embed.min.js?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/imagesloaded.pkgd.min.js
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/isotope.pkgd.min.js
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/jquery.qtip.min.js
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/ac-js.js
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/fancybox/lib/jquery.mousewheel-3.0.6.pack.js
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/fancybox/source/jquery.fancybox.pack.js
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/fancybox/source/helpers/jquery.fancybox-media.js?v=1.0.6

File size of all javascript files combined

0.00

Javascript minifying

Great! The Javascript files are minified.

Speed test – CSS

CSS

Error! Too many CSS files detected that slows down the page load.

http://www.mpmcapital.com/wp-content/plugins/contact-form-7/includes/css/styles.css?ver=4.7
http://www.mpmcapital.com/wp-content/plugins/photo-gallery/css/bwg_frontend.css?ver=1.3.42
http://www.mpmcapital.com/wp-content/plugins/photo-gallery/css/font-awesome/font-awesome.css?ver=4.6.3
http://www.mpmcapital.com/wp-content/plugins/photo-gallery/css/jquery.mCustomScrollbar.css?ver=1.3.42
http://www.mpmcapital.com/wp-content/plugins/photo-gallery/css/sumoselect.css?ver=3.0.2
http://www.mpmcapital.com/wp-content/themes/mpm-capital/css/vendor/bigvideo.css?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/css/vendor/flexslider.css?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/css/vendor/mediaBoxes.css?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/css/main.css?ver=4.7.5
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/jquery.qtip.min.css
http://www.mpmcapital.com/wp-content/themes/mpm-capital/js/fancybox/source/jquery.fancybox.css

File size of all css files combined

0.00

CSS minifying

Great! The CSS elements are minified.

Speed test – Compression

Uncompressed size of the of the HTML

0.00

Gzip compression

Your site uses compression.

Speed test – Browser cache

Browser cache

The browser cache is set correctly for all elements.

Speed test – Images

File size of all images combined

0.00

Image optimisation

All images are optimized.

Links

We found a total of 104 different links.
Internal links: 46
External links: 58

External links:

Link text (anchor)	Link strength
Investor Login
Watch Now
see full map / get directions
see full map / get directions
Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform
Harpoon Therapeutics Announces Completion of $45M Series B Financing
MPM Portfolio Company True North Therapeutics Acquired by Bioverativ, Inc
Syndax Shares Soar as Lead Drug Clears a Mid-Stage Cancer Drug Study Hurdle
Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis
Inside Perspectives on Cancer Immunotherapy: An Interview with MPM’s Christiana Bardon
FDA Approves MPM Portfolio Company Radius Health’s TYMLOS™ (abaloparatide)
Meet One the Most Successful German Biotech Leaders Ever Read more about MPM’s Patrick Baeuerle
MPM Managing Director Chris Bardon Named a Top-40 Transformer
MPM Portfolio Company Oncorus Nominated for 2017 NEVY Award as Hottest Early-Stage Startup Therapeutics
Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors
Rhythm Announces Completion of $41 Million Mezzanine Financing
MPM Portfolio Company Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies
Accomplished Biotech Investor Ed Hurwitz Joins MPM as Managing Director
MPM Portfolio Company, Astute Medical, Forms Strategic Partnership with Bio-Techne
Novartis Signs Exclusive Option, Collaboration and License Agreement with MPM Portfolio Company Conatus Pharmaceuticals Inc.
Oncorus®, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLC
Chris Bardon, MPM Managing Director, Comments to Bloomberg on New Approaches to Medical Philanthropy
Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Tumor Program Update
Novartis Acquires MPM Portfolio Company Selexys Pharmaceuticals Corporation and SelG1 Antibody for Reduction of Pain Crises in Sickle Cell Disease
Harpoon Therapeutics Appoints Hans-Peter Gerber, PhD, As Chief Scientific Officer
Semma Therapeutics Announces Mark Fishman, M.D. Has Joined Its Board of Directors as Chairman
MPM Portfolio Company Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer Institute
Motus Therapeutics Inc., a Subsidiary of MPM Portfolio Company Rhythm Holding Co., LLC is to be Acquired by Allergan
True North Therapeutics Announces $45 Million Series D Financing
Pacira Pharmaceuticals’ Kristen Williams is Honored as 1 of 15 “Fierce Women in Biopharma 2016”
Three MPM Portfolio Companies (Blade, Oncorus & Rhythm) Named to FierceBiotech’s “2016 Fierce 15” List
Radius Announces Publication of Additional Positive Results from the Phase 3 Active Trial of Osteoporosis Treatment
NY Times
Press Release
Aratana Secures Third FDA Approval
Harvard Medical School Appoints MPM Medical and Scientific Advisory Co-Chair George Daley as New Dean
Astellas and MPM Capital Launch DigiTx Partners
Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity
Former Bluebird Bio (BLUE) CSO Takes the Reins at Oncorus; Startup Launches with $57 Million Series A
MPM Portfolio Company Semma Therapeutics Featured in Boston Globe
Chris Bardon, Managing Director for the Oncology Impact Fund, on Bloomberg Capital Markets
Aratana Therapeutics Granted First FDA Approval
Tizona Therapeutics, Inc., Completes $43 Million Series B Financing
Radius Health Submits New Drug Application to the U.S. Food and Drug Administration for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis
Cerecor Announces Pricing of Initial Public Offering
Semma Therapeutics named FierceMedicalDevices’ 2015 Fierce 15
Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab
Rhythm Subsidiary Raises $40 Million in Oversubscribed Financing
Taking Clinical Trials Out of the Dark Ages (Clinical Ink)
Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly
Biotech Startup to Fight Diabetes on the Cellular Front
Chiasma Announces Mark Leuchtenberger as Chief Executive Officer
Radius (RDUS) Announced Today That It Has Acquired The License To Develop And Market RAD1901 In Japan
Chiasma Appoints David Stack as Chairman of the Board; John A. Scarlett, M.D. Joins Board of Directors
Syndax Says Immuno-oncology Discovery Happened Instead of an IPO
Radius: The Top Performing IPO of 2014
Aratana Featured: Start-Ups Work on Biotech Drugs for Pets
Cerecor Inc. Closes on Initial Tranche of US$32M Series B Financing

Internal links:

Link text (anchor)	Link strength
http://www.mpmcapital.com
http://www.mpmcapital.com/#
Home
Companies
Team
Contact
Press
COSTIM
CoStim
Print
Terms Of Use & Disclosures
Chris Varma, Co-founder and Former President and CEO of Blueprint Medicines, Joins MPM as Entrepreneur-in-Residence
True North Therapeutics Receives FDA Orphan Drug Designation for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD)
Tizona Therapeutics, Inc. Appoints George Golumbeski, Ph.D., to its Board of Directors
Osteoporosis, a Disease With Few Treatment Options, May Soon Have One More
TriNetX Enters into Collaboration with Celgene
Aratana Therapeutics Granted FDA Approval of ENTYCE®
MPM Launches $471 Million Social Impact Oncology Fund
UBS Cancer Fund Shows Power of Impact Investing
UBS, MPM Seek Big ‘Impact’ in Cancer Drugs with $471M Fund
UBS Raises Record $471 Million for Oncology Impact Fund
Syndax Raises $80 Million in Series C Financing
Epizyme Appoints Robert Bazemore President and Chief Executive Officer
Briggs W. Morrison, M.D., CEO of Syndax, Appointed Key Strategic Advisor to MPM Capital
K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific Advisor
MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company Vesuvius
MPM closes $400 million fund
23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc.
Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics
Novartis International Global Head M&A and Licensing Anthony Rosenberg to join as Managing Director, effective April 1, 2015
Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Signs Agreement with Global Pharmaceutical Company
Ebb & Flow: Chiasma’s Private Decision
23andMe to Create Therapeutics Group, Appoints Scientific Luminary, R&D Executive Richard Scheller, Ph.D. to Lead
MPM Capital Announces Immuno-Oncology Pioneer Patrick Baeuerle to serve as Managing Director
Chiasma Announces Completion of $70 Million Series E Financing
Chiasma Inc. Releases Newly Published Phase 3 Study Results
Radius Announces Positive Phase 3 Top-Line Results
For Venture Capital, Biotech is Where It’s Really At
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin
True North snags $22M and sets course for the clinic with a rare disease drug
iPierian acquired by Bristol-Myers Squibb
Iconic Therapeutics Raises $20 Million to Advance Clinical Development of Wet AMD Program
CoStim Pharmaceuticals, Inc. Acquired by Novartis
MPM Capital and Kleiner Perkins Caufield & Byers top the list of investors with the most 2013 IPOs
Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone
back to top

Website security

104.197.111.156

External hidden links

Good! No hidden external links found

Looking for eval()

Good! No eval(bas64_decode()) scripts are found

Checking for XSS vulnerability

No XSS vulnerability found

Email encryption

Warning! The website contains at least one unencrypted email address.

Sites on same ip

hrispayrollsoftware.com

ledesignjournal.com

hrpayrollsystems.net

livelifesafaris.com

applicanttrackingsystems.net

integratedsafety.ca

greenersavingsfewerrepairs.com

connectmplsfoundation.org

ranchowildlife.org

Icons

Favicon

Good! The website uses favicon.

Typos

pmcapital.com, mnpmcapital.com, npmcapital.com, mhpmcapital.com, hpmcapital.com, mpmcapital.com, pmcapital.com, mjpmcapital.com, jpmcapital.com, mkpmcapital.com, kpmcapital.com, mlpmcapital.com, lpmcapital.com, m pmcapital.com, pmcapital.com, mmcapital.com, mpomcapital.com, momcapital.com, mplmcapital.com, mlmcapital.com, mp0mcapital.com, m0mcapital.com, mp-mcapital.com, m-mcapital.com, mpmcapital.com, mmcapital.com, mp_mcapital.com, m_mcapital.com, mpcapital.com, mpmncapital.com, mpncapital.com, mpmhcapital.com, mphcapital.com, mpmcapital.com, mpcapital.com, mpmjcapital.com, mpjcapital.com, mpmkcapital.com, mpkcapital.com, mpmlcapital.com, mplcapital.com, mpm capital.com, mp capital.com, mpmapital.com, mpmcxapital.com, mpmxapital.com, mpmcsapital.com, mpmsapital.com, mpmcapital.com, mpmapital.com, mpmcdapital.com, mpmdapital.com, mpmcfapital.com, mpmfapital.com, mpmcvapital.com, mpmvapital.com, mpmc apital.com, mpm apital.com, mpmcpital.com, mpmcaqpital.com, mpmcqpital.com, mpmcawpital.com, mpmcwpital.com, mpmcazpital.com, mpmczpital.com, mpmcapital.com, mpmcpital.com, mpmcaxpital.com, mpmcxpital.com, mpmcaspital.com, mpmcspital.com, mpmcaital.com, mpmcapoital.com, mpmcaoital.com, mpmcaplital.com, mpmcalital.com, mpmcap0ital.com, mpmca0ital.com, mpmcap-ital.com, mpmca-ital.com, mpmcapital.com, mpmcaital.com, mpmcap_ital.com, mpmca_ital.com, mpmcaptal.com, mpmcapiutal.com, mpmcaputal.com, mpmcapijtal.com, mpmcapjtal.com, mpmcapital.com, mpmcaptal.com, mpmcapiltal.com, mpmcapltal.com, mpmcapiotal.com, mpmcapotal.com, mpmcapi8tal.com, mpmcap8tal.com, mpmcapi9tal.com, mpmcap9tal.com, mpmcapi*tal.com, mpmcap*tal.com, mpmcapial.com, mpmcapitral.com, mpmcapiral.com, mpmcapitfal.com, mpmcapifal.com, mpmcapitgal.com, mpmcapigal.com, mpmcapithal.com, mpmcapihal.com, mpmcapityal.com, mpmcapiyal.com, mpmcapit5al.com, mpmcapi5al.com, mpmcapit6al.com, mpmcapi6al.com, mpmcapitl.com, mpmcapitaql.com, mpmcapitql.com, mpmcapitawl.com, mpmcapitwl.com, mpmcapitazl.com, mpmcapitzl.com, mpmcapital.com, mpmcapitl.com, mpmcapitaxl.com, mpmcapitxl.com, mpmcapitasl.com, mpmcapitsl.com, mpmcapita.com, mpmcapitalp.com, mpmcapitap.com, mpmcapitalo.com, mpmcapitao.com, mpmcapital.com, mpmcapita.com, mpmcapitali.com, mpmcapitai.com, mpmcapitalk.com, mpmcapitak.com, mpmcapitalm.com, mpmcapitam.com, mpmcapital..com, mpmcapita..com

More Sites

trendsforbusiness.nl

Title: Dit domein is gereserveerd | KPN Internedservices
Description:
Sites loading time: 380
Internet Protocol (IP) address:
Javascript total size: 0.00B
CSS total size: 3.50KB
Image total size: 123.01KB
Total size: 133.29KB
Tech:
- Other
  - CSS (Cascading Style Sheets)
  - Html (HyperText Markup Language)
  - Iframe

hoteldiagonalplazazaragoza.com

Title: Hotel en Zaragoza Hoteles SantoS Diagonal Plaza **** web oficial - Hotel Zaragoza Aeropuerto Feria de Zaragoza Congresos hoteles en Zaragoza Ofertas Hoteles de Zaragoza aeropuerto - Hotel Diagonal Plaza Zaragoza
Description: Hotel en Zaragoza Diagonal Plaza junto al Aeropuerto de Zaragoza Palacio de Congresos Expo de Zaragoza Hoteles Santos en Zaragoza Hoteles de Congresos e Incentivos Aeropuerto Hotel especializado en Eventos, Bodas en Zaragoza, Congresos en Zaragoza Convenciones. Junto a Caja Zaragoza y caja rural de Zaragoza.
Internet Protocol (IP) address:
Tech:
- Other
  - Html (HyperText Markup Language)

troutfamilycleaning.com

Title: Trout Family Cleaning Services, LLC
Description: We're a family, not a franchise! We do house cleaning, commercial cleaning, move in/out cleaning, post-construction cleaning and more.
Internet Protocol (IP) address:
Tech:
- Analytic
  - Google Analytics
- Other
  - CSS (Cascading Style Sheets)
  - Google Font API
  - Html (HyperText Markup Language)
  - Html5
  - Javascript

careertechcentre.com

Title: 鵲亜賀紗のおくりもの情報
Description:
Internet Protocol (IP) address:
Tech:
- CMS
  - Wordpress CMS
- Other
  - CSS (Cascading Style Sheets)
  - Html (HyperText Markup Language)
  - Html5
  - Javascript
  - Php (Hypertext Preprocessor)
  - Pingback

rkvadventure.in

Title: RKV Adventure & Aero-Sports
Description: We provide flying, camping, hang glider, ultra light aircraft, microlight aircraft,
Internet Protocol (IP) address:
Tech:
- Analytic
  - Google Analytics
- Other
  - CSS (Cascading Style Sheets)
  - Html (HyperText Markup Language)
  - Html5
  - Javascript

totalimobiliaria.com

Title: Total Imoveis - A sua imobiliaria.
Description: Imóveis em Barretos - SP, Imóveis em Campina Verde - MG, Imóveis em Campo Florido-MG, Imóveis em Comendador Gomes - MG, Imóveis em Fronteira - MG, Imóveis em Frutal-MG, Imóveis em Itapagipe - MG, Imóveis em Planura - MG, Imóveis em Ribeirão Preto - SP, A sua imobiliaria.
Sites loading time: 27421
Internet Protocol (IP) address:
Javascript total size: 345.24KB
CSS total size: 142.46KB
Image total size: 572.25KB
Total size: 1.14MB
Tech:
- Social
  - Facebook Box
- Other
  - CSS (Cascading Style Sheets)
  - Html (HyperText Markup Language)
  - Html5
  - Javascript
  - Php (Hypertext Preprocessor)

shreeumaelectrotech.com

Title: Shree Uma Electrotech Institute
Description:
Internet Protocol (IP) address:
Tech:
- Other
  - CSS (Cascading Style Sheets)
  - Html (HyperText Markup Language)
  - Html5
  - Javascript
  - Php (Hypertext Preprocessor)

zakelijk-bankieren.nl

Title: Zakelijk Bankieren > Informatie, tips, overzicht, tarieven
Description: Zakelijk Bankieren > Hier vind je informatie en tips over het openen van een zakelijke bankrekening. Overzicht banken, tarieven, internet bankieren, boekhouding, krediet etc.
Sites loading time: 1331
Internet Protocol (IP) address:
Javascript total size: 445.93KB
CSS total size: 4.20KB
Image total size: 68.67KB
Total size: 560.72KB
Tech:
- Analytic
  - Google Analytics
- Advertisement
  - Google Adsense
- Other
  - CSS (Cascading Style Sheets)
  - Html (HyperText Markup Language)
  - Javascript

trans4mationhealthandwellness.com

Title: Trans4mation Health and Wellness
Description:
Internet Protocol (IP) address:
Tech:
- Analytic
  - Google Analytics
- Other
  - CSS (Cascading Style Sheets)
  - Html (HyperText Markup Language)
  - Html5
  - Javascript

laurindasminipreschool.com

Title: Laurinda's Mini-Preschool
Description: Home preschool
Internet Protocol (IP) address:
Tech:
- Analytic
  - Google Analytics
- Social
  - Add This
- Other
  - CSS (Cascading Style Sheets)
  - Google Font API
  - Html (HyperText Markup Language)
  - Html5
  - Javascript

SEO report of mpmcapital.com

MPM Capital - Powering Breakthroughs in Life Sciences

Tasks

SEO

Social

Content

Readability

Technologies

Speed test

Speed test – Javascript

Speed test – CSS

Speed test – Compression

Speed test – Browser cache

Speed test – Images

Links

External links:

Internal links:

Website security

Sites on same ip

hrispayrollsoftware.com

ledesignjournal.com

hrpayrollsystems.net

livelifesafaris.com

applicanttrackingsystems.net

integratedsafety.ca

mpmcapital.com

greenersavingsfewerrepairs.com

connectmplsfoundation.org

ranchowildlife.org

Icons

Typos

More Sites

About

Follow Us On

Say hello